Press Release

Home / Press Release

AMP to supply the growing Germany market with pharmaceutical medical cannabis imported from Canada ERFURT and BERLIN, Germany, October 15, 2019 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) through its wholly-owned subsidiary AMP Alternative Medical Products GmbH (“AMP Germany”) has entered into a four-year, non-exclusive, distribution agreement with CC Pharma GmbH (“CC Pharma”), a leading distributer of EU-pharmaceuticals products to more than 13,000 pharmacies throughout Germany.  The agreement provides for monthly shipments of imported European Union...

BERLIN, Germany, October 10, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that it has begun conducting an European Union (EU) Good Manufacturing Procedure (EU-GMP) audit of its supply chain logistics in Germany to ensure that the quality and integrity of pharmaceutical goods during transportation and storage is maintained throughout the supply chain from the supplier to the German patient.     EU-GMP certification is an internationally recognized system that ensures all pharmaceutical goods, including medical cannabis,...

BERLIN, Germany, October 8, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that it has entered into a non-binding memorandum of understanding to purchase up to 1,200 kilograms of either branded or white-labeled European Union - Good Manufacturing Practice (EU-GMP) medical cannabis flower annually from an Alberta based supplier with a cultivation and processing licence from Health Canada (“Alberta LP”).        AMP and the Alberta LP will begin imports upon the Alberta LP receiving a sales...

BERLIN, Germany, September 17, 2019 –– AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces that one of its prospective medical cannabis supplier, Pure Life Cannabis Corp. (“Pure Life”), has completed its European Union Good Manufacturing Practice (“EU-GMP”) gap analysis and will undergo an EU-GMP audit before calendar year-end.  Upon passing the EU-GMP audit, Pure Life will be subject to an EU-GMP inspection and certification by German State officials.       AMP and Pure Life announced on February 7, 2019...

BERLIN, Germany, September 6, 2019 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX), (FSE: C4T, ISIN: CA00176G1028) announces that it has granted incentive stock options to purchase up to 2,120,000 common shares of the Company to certain directors, officers, employees and consultants in accordance with its stock option plan, including options to purchase up to 1,175,000 shares to certain directors and officers. Each option vests immediately has an exercise price of $0.50 per share and is exercisable...

BERLIN, Germany, September 4, 2019 – AMP German Cannabis Group Inc. ("AMP" or the "Company") (formerly "Chinook Tyee Industry Limited") (CSE: XCX), (FSE: C4T), (ISIN: CA00176G1028) announces the commencement of trading of its common shares on the Canadian Securities Exchange (CSE).  The Company's common shares were delisted from the TSX Venture Exchange at the close of market on September 3, 2019. The Company also announces that it has updated investment policy to enhance shareholder value from investments in the European medical...

BERLIN, Germany, August 22, 2019 – Chinook Tyee Industry Limited ("Chinook" or the "Company") (TSXV: XCX), (Frankfurt: C4T: ISIN: CA16961T2083) announces that the Canadian Securities Exchange ("CSE") has approved the listing of the Company's Class A Voting Common Shares Without Par Value ("Common Shares") and will begin trading at market open on September 4, 2019 under the Company's current symbol, "XCX" ("CSE Listing").  The Company also announces that it has changed its name to "AMP German Cannabis Group Inc." and its...

Chinook Insiders are the largest investors in the Series A financing as its German subsidiary expands in the European medical cannabis industry BERLIN, Germany, June 12th, 2019 – Chinook Tyee Industry Limited ("Chinook") (TSXV: XCX), (Frankfurt: C4T, ISIN: CA16961T2083) completed its Series A non-brokered placement (Private Placement) of 10,000,000 Common Shares at a subscription price of $0.15 per Common Share (Common Shares), raising $1,500,000, which Chinook intends to use for working capital purposes. All securities issued pursuant to the Private Placement will be subject to a...

Chinook establishes EU-GMP standards for its imports of medical cannabis to Germany from Canada   BERLIN, Germany, May 29, 2019 /CNW/ - Chinook Tyee Industry Limited ("Chinook") (TSXV: XCX), (Frankfurt: C4T, ISIN: CA16961T2083) has entered into a consulting agreement with a leading German pharmaceutical and medical consulting company, pursuant to which, among other things, the consultant shall evaluate and confirm that medical cannabis produced by a Canadian licensed producer of cannabis (a "LP") that has entered into a supply agreement with Chinook meets EU-GMP regulations for importing medical cannabis into Germany from...

BERLIN, Germany, May 8th, 2019 – Chinook Tyee Industry Limited ("Chinook") (TSXV: XCX) (FSE: C4T), has granted incentive stock options to purchase up to 1,020,000 common shares of Chinook to its directors, officers, employees, and consultants in Germany, Switzerland and Canada pursuant to its stock option plan, including 655,000 options issued to directors and officers. Each option vests immediately, has an exercise price of $0.15 per share and is valid for a period of one year from the date of issuance.   Chinook Tyee Industry Limited Chinook is...